연구성과로 돌아가기
2022 연구자 정보 (71 / 1074)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Meinhardt, Gerold (Meinhardt, G) |
Daiichi Sankyo, Basking Ridge, NJ USA |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Modi, Shanu (Modi, S) |
제1저자 |
Mem Sloan Kettering Canc Ctr, Montpellier, France Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | |
|
Negro, Alejandra (Negro, A) |
Astrazeneca, Gaithersburg, MD USA |
|
|
[JCR상위 2.7] Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348) [JCR상위 5.9] OUTCOMES BY BASELINE LIVER FUNCTION IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA TREATED WITH TREMELIMUMAB AND DURVALUMAB IN THE PHASE 3 HIMALAYA STUDY |
SCIE | 2.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
|||
|
Niikura, Naoki (Niikura, N) |
Tokai Univ, Sch Med, Isehara, Japan |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Oh, Tae Gyu (Oh, TG) |
Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA |
|
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | ||
|
Paik, Man-Jeong (Paik, MJ) |
Sunchon Natl Univ, Coll Pharm, Sunchon, South Korea |
|
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | ||
|
Pandol, Stephen J. (Pandol, SJ) |
Cedars Sinai Med Ctr, Cedars Sinai Canc, Los Angeles, CA 90048 USA Cedars Sinai Med Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA |
|
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | ||
|
Park, Jee-Young (Park, JY) |
|
|
[JCR상위 2.7] Lactate dehydrogenase as a surrogate marker for both PCR and survival in breast cancer patients who underwent neoadjuvant chemotherapy. | SCIE | 2.7 | ONCOLOGY | ||||
|
Park, Yeon Hee (Park, YH) |
Samsung Med Ctr, Seoul, South Korea |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Rotter, Jerome, I (Rotter, J) |
Harbor UCLA Med Ctr, Inst Translat Genom & Populat Sci, Lundquist Inst Biomed Innovat, Dept Pediat, Torrance, CA 90509 USA Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA |
AAY-6598-2021 Rotter, Jerome |
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | ||
|
Shin, Hyemi (Shin, H) |
Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea |
|
0000-0002-7445-7834 Shin, Hyemi |
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | ||
|
Shoji, Takashi (Shoji, T) |
Kyoto Univ, Dept Med, Kyoto, Japan |
|
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | ||
|
Sohn, Joohyuk (Sohn, J) |
Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea |
|
0000-0002-2303-2764 Sohn, Joohyuk |
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Suresh, S. (Suresh, S) |
Maulana Azad Natl Inst Technol, Dept Chem Engn, Bhopal 462003, Madhya Pradesh, India |
|
|
[JCR상위 2.7] Occurrence, transformation, bioaccumulation, risk and analysis of pharmaceutical and personal care products from wastewater: a review | SCIE | 2.7 | CHEMISTRY, MULTIDISCIPLINARY;ENGINEERING, ENVIRONMENTAL;ENVIRONMENTAL SCIENCES | ushuats@gmail.com;elza.bontempi@unibs.it; | ||
|
Tai, Wai Meng David (Tai, WMD) |
|
|
[JCR상위 2.7] Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348) | SCIE | 2.7 | ONCOLOGY |
페이지 이동: